BlackRock Investment Management, LLC - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 21 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2015. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
BlackRock Investment Management, LLC ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q4 2016$8,000
+14.3%
3,0030.0%0.00%
Q3 2016$7,0000.0%3,0030.0%0.00%
Q2 2016$7,000
-12.5%
3,0030.0%0.00%
Q1 2016$8,000
-11.1%
3,0030.0%0.00%
Q4 2015$9,000
+50.0%
3,003
+13.6%
0.00%
Q3 2015$6,000
-40.0%
2,6440.0%0.00%
Q2 2015$10,0002,6440.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q2 2015
NameSharesValueWeighting ↓
SABBY MANAGEMENT, LLC 242,850$923,0000.13%
ABNER HERRMAN & BROCK LLC 241,500$918,0000.13%
Weaver Consulting Group 48,881$186,0000.10%
Tibra Equities Europe Ltd 87,000$331,0000.10%
Ikarian Capital, LLC 293,200$1,115,0000.09%
GSA CAPITAL PARTNERS LLP 60,238$229,0000.03%
Ergoteles LLC 124,329$472,0000.01%
CFO4Life Group, LLC 12,003$46,0000.01%
HighPoint Advisor Group LLC 17,033$65,0000.01%
BOOTHBAY FUND MANAGEMENT, LLC 32,836$125,0000.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders